Wutah dodolan YoY sajrone 12 wulan kepungkur: regeneron.com (REGN)

Regeneron Pharmaceuticals (REGN) minimizes risks through a diversified drug portfolio, while the modernization of bioreactors exponentially increases antibody production. Year-over-year sales dynamics over the last four quarters allow for the filtering of market noise, while 18.60 reflects the latest metric value. Robust patent protection for its blockbusters provides the company with benchmark margins and a steady stream of free cash flow.
regeneron.com (REGN) - rincian metrik lan laporan keuangan

Controlling its own antibody production capacities while moderately utilizing external CRO contractors allows Regeneron Pharmaceuticals (REGN) to directly transform R&D successes into revenue. The year-over-year sales growth rate (over 4 quarters) measures the expansion pace of this stream through a rolling annual window, neutralizing reporting seasonality and demonstrating the business's operational resilience in real-time.